1 tim. 14 min
#8 Florian Brand & Christian Angermayer: A Higher Calling 52 Insights Podcast
-
- Samhälle och kultur
Imagine a future where your local therapist is able to administer a small dose of a psychedelic compound to you in a controlled setting. Whatever mental health affliction your experiencing, be it addiction, anxiety or depression, your ability to gain fast, effective respite to many could be life-transformative.
This is the future that atai is betting on, a German-based psychedelic inspired pharmaceutical company with a slew of drugs in current development. Co-founded by the entrepreneurial trendsetter Christian Angermayer and Florian Brand, they stand on the shoulders of giants, partly assisted by the decades of research by mavericks in white coats such as Rolland Griffiths, David Nutt and Rick Doblin. They aim to revolutionise the mental health landscape for hundreds of millions of sufferers worldwide.
Having just IPO'd in what is becoming a crowded marketplace for psychedelic inspired life science companies, they are betting on psychedelic inspired compounds like ibogaine, DMT and ketamine to reinvigorate and empower large sections of society where SSRIs (Selective serotonin reuptake inhibitor) have only done half the job. And they mean business, they count luminaries like Sam Harris, investor giant Peter Thiel and artists Diplo & One Direction's Liam Payne as backers for this juggernaut.
However, the challenge for atai remains twofold, one, to dispense of the century-long stigmas and myths that cling to psychedelics and mental health but also to sell this into to a weary public. In this discussion, Florian and Christian talk me through their future roadmap, why psychedelics changed their lives and when can we expect these medicinal compounds to appear over the counter?
Imagine a future where your local therapist is able to administer a small dose of a psychedelic compound to you in a controlled setting. Whatever mental health affliction your experiencing, be it addiction, anxiety or depression, your ability to gain fast, effective respite to many could be life-transformative.
This is the future that atai is betting on, a German-based psychedelic inspired pharmaceutical company with a slew of drugs in current development. Co-founded by the entrepreneurial trendsetter Christian Angermayer and Florian Brand, they stand on the shoulders of giants, partly assisted by the decades of research by mavericks in white coats such as Rolland Griffiths, David Nutt and Rick Doblin. They aim to revolutionise the mental health landscape for hundreds of millions of sufferers worldwide.
Having just IPO'd in what is becoming a crowded marketplace for psychedelic inspired life science companies, they are betting on psychedelic inspired compounds like ibogaine, DMT and ketamine to reinvigorate and empower large sections of society where SSRIs (Selective serotonin reuptake inhibitor) have only done half the job. And they mean business, they count luminaries like Sam Harris, investor giant Peter Thiel and artists Diplo & One Direction's Liam Payne as backers for this juggernaut.
However, the challenge for atai remains twofold, one, to dispense of the century-long stigmas and myths that cling to psychedelics and mental health but also to sell this into to a weary public. In this discussion, Florian and Christian talk me through their future roadmap, why psychedelics changed their lives and when can we expect these medicinal compounds to appear over the counter?
1 tim. 14 min